Invivyd Completes Enrollment in Phase 3 LIBERTY Trial for COVID-19 Antibody VYD2311; Results Expected Q3 2026
IVVD sits 82% above its 52-week low of $0.483 on elevated volume (3.7× avg).
Summary
Invivyd announced the completion of enrollment for its Phase 3 LIBERTY clinical trial, which compares its VYD2311 COVID-19 antibody to an mRNA vaccine. This marks a significant step in the company's VYD2311 development program, following the dosing of the first participants in this trial on June 9th and the completion of enrollment for its DECLARATION trial on June 1st. The progress is crucial given the company's substantial R&D investment in VYD2311, as highlighted in its Q1 earnings. Initial results from the LIBERTY study are anticipated in the third quarter of 2026.
At the time of this announcement, IVVD was trading at $0.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $255.9M. The 52-week trading range was $0.48 to $3.07. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.